Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T14:46:36.638Z.
Calculation as of: 2026-10-06T14:46:36.638Z.
Quote observation: 2026-10-06T14:45:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fb57f85ed843ad7a76bd5b785e55fde6d0feef1b4d3f081c49812093a2178ef2
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$122.96M
PS Ratio
36.23
TTM Avg
108.18
3Y Avg
108.18
5Y Avg
108.18
Market Cap
$117.86M
PS Ratio
70.57
TTM Avg
60.78
3Y Avg
38.49
5Y Avg
33.17
Market Cap
$116.99M
PS Ratio
11.66
TTM Avg
17.12
3Y Avg
13.55
5Y Avg
29.14
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| enGene Holdings Inc. (ENGN) | $121.22M | N/A | N/A | N/A | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $119.72M | N/A | N/A | N/A | N/A |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $122.96M | 36.23 | 108.18 | 108.18 | 108.18 |
| Cibus, Inc. (CBUS)vs › | $123.66M | 28.45 | 25.82 | 87.76 | 78.89 |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $117.86M | 70.57 | 60.78 | 38.49 | 33.17 |
| LENZ Therapeutics, Inc. (LENZ)vs › | $117.57M | 5.47 | 34.83 | 63.67 | 63.67 |
| Caribou Biosciences, Inc. (CRBU)vs › | $116.99M | 11.66 | 17.12 | 13.55 | 29.14 |
| Entera Bio Ltd. (ENTX)vs › | $126.43M | N/A | 643.32 | 865.94 | 547.59 |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.65M | 21.06 | 26.20 | 23.47 | 109.55 |
| MaxCyte, Inc. (MXCT)vs › | $114.62M | 3.69 | 3.79 | 7.32 | 10.74 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q4 FY2025Period ended 2025-10-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-12-22 |
| Q1 FY2026Period ended 2026-01-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-09 |
| Q2 FY2026Period ended 2026-04-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-06-15 |
| Q3 FY2026Period ended 2026-07-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-09-08 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
